{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:17:02Z","timestamp":1770434222190,"version":"3.49.0"},"reference-count":10,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":6633,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1990,5]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>Twenty\u2010two hyperprolactinaemic women were randomly allocated to two groups and treated with bromocriptine or the new, non\u2010ergot, long\u2010acting dopamine agonist, CV 205\u2010502. The study was double\u2010blind for 6 months. Four patients in the bromocriptine group, but none in the CV 205\u2010502 group, discontinued the study because of adverse reactions. Adverse reactions in those receiving the new drug were milder and more transient than with bromocriptine. With once\u2010daily doses of 0.075 mg CV 205\u2010502, eight of 11 women achieved normal PRL concentrations after 8 weeks treatment (median (95% confidence limits), 352 (70\u2010987) mU\/1) compared with two of nine receiving a divided daily dose of 5 mg bromocriptine (1802 (1205\u20104438) mU\/1) (P &lt; 0.002). With doses of 0.075\u20100.15 mg of CV 205\u2010502, 10 of 11 women achieved normal PRL concentrations at 24 weeks compared with three of the remaining seven women on doses of 5\u201010 mg of bromocriptine. Regular menstrual bleeding was restored and galactorrhoea relieved in the majority of patients, with marginally greater efficacy with CV 205\u2010502. CV 205\u2010502 is highly effective for the long\u2010term treatment of hyperprolactinaemia. It is better tolerated than bromocriptine, is effective in a once\u2010daily dose, appears to be safe, and provides a valuable alternative to the dopamine agonist drugs in use today.<\/jats:p>","DOI":"10.1111\/j.1365-2265.1990.tb00899.x","type":"journal-article","created":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T12:06:14Z","timestamp":1205755574000},"page":"565-572","source":"Crossref","is-referenced-by-count":38,"title":["A DOUBLE\u2010BLIND STUDY COMPARING A NEW NON\u2010ERGOT, LONG\u2010ACTING DOPAMINE AGONIST, CV 205\u2010502, WITH BROMOCRIPTINE IN WOMEN WITH HYPERPROLACTINAEMIA"],"prefix":"10.1111","volume":"32","author":[{"given":"ROY","family":"HOMBURG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHRISTINE","family":"WEST","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JUDITH","family":"BROWNELL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HOWARD S.","family":"JACOBS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03347152"},{"key":"e_1_2_1_3_1","first-page":"39","volume-title":"Liber Amicorum E. W. Fluckiger","author":"Fluckiger W. E.","year":"1988"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-595X(83)80059-0"},{"key":"e_1_2_1_5_1","first-page":"305","volume-title":"Endocrinology '85","author":"Gaillard R.","year":"1986"},{"key":"e_1_2_1_6_1","first-page":"83","article-title":"Bromocriptine for induction of ovulation in hyperprolactinaemic amenorrhoea. Modern trends","volume":"15","author":"Nillius S.","year":"1984","journal-title":"Acta Europaea Fertilitatis"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1987.tb00789.x"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1988.tb01225.x"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-50-6-1026"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/09513599809029348"},{"key":"e_1_2_1_11_1","first-page":"287","article-title":"Effects of two novel dopaminergic drugs, CV 205\u2010502 and CQP 201\u2010403, on prolactin and growth hormone secretion by human pituitary tumors in vitro","volume":"116","author":"Venetikou M. S.","year":"1987","journal-title":"Acta Endocrinologica"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.1990.tb00899.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.1990.tb00899.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T20:30:03Z","timestamp":1698006603000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.1990.tb00899.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,5]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1990,5]]}},"alternative-id":["10.1111\/j.1365-2265.1990.tb00899.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.1990.tb00899.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,5]]}}}